These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 25560711

  • 1. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.
    Ann Intern Med; 2015 Jan 06; 162(1):1-10. PubMed ID: 25560711
    [Abstract] [Full Text] [Related]

  • 2. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 3. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R.
    Ann Intern Med; 2010 Jun 15; 152(12):761-9. PubMed ID: 20547904
    [Abstract] [Full Text] [Related]

  • 4. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 15; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 5. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 6. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser IA, Alshuth U, Kliem V.
    Transplantation; 2018 May 27; 102(5):876-882. PubMed ID: 29166336
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 27; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 9. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
    Kalil AC, Freifeld AG, Lyden ER, Stoner JA.
    PLoS One; 2009 Oct 27; 4(5):e5512. PubMed ID: 19436751
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
    Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC.
    Am J Transplant; 2006 Sep 27; 6(9):2134-43. PubMed ID: 16780548
    [Abstract] [Full Text] [Related]

  • 11. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A, RESITRA.
    Clin Infect Dis; 2008 Jan 01; 46(1):20-7. PubMed ID: 18171208
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 01; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 13. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 14. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L, Wang Y, Yan CH, Huang XJ.
    Zhonghua Nei Ke Za Zhi; 2018 Mar 01; 57(3):191-195. PubMed ID: 29518863
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M.
    Clin J Am Soc Nephrol; 2015 Feb 06; 10(2):294-304. PubMed ID: 25424991
    [Abstract] [Full Text] [Related]

  • 16. [Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation].
    Wang Y, Huang XJ, Xu LP, Liu DH, Chen YH, Han W, Wang J, Liu KY.
    Zhonghua Yi Xue Za Zhi; 2008 Dec 16; 88(46):3265-7. PubMed ID: 19159551
    [Abstract] [Full Text] [Related]

  • 17. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
    Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, Palau J, Romero M, Montava A, Senent L, Martínez J, Jarque I, Salavert M, Córdoba J, Gómez L, Weiss S, Moscardó F, de la Rubia J, Larrea L, Sanz MA, Sanz GF.
    Biol Blood Marrow Transplant; 2009 Jun 16; 15(6):730-40. PubMed ID: 19450758
    [Abstract] [Full Text] [Related]

  • 18. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2008 Feb 16; 14(2):240-4. PubMed ID: 18236404
    [Abstract] [Full Text] [Related]

  • 19. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
    Limaye AP, Stapleton RD, Peng L, Gunn SR, Kimball LE, Hyzy R, Exline MC, Files DC, Morris PE, Frankel SK, Mikkelsen ME, Hite D, Enfield KB, Steingrub J, O'Brien J, Parsons PE, Cuschieri J, Wunderink RG, Hotchkin DL, Chen YQ, Rubenfeld GD, Boeckh M.
    JAMA; 2017 Aug 22; 318(8):731-740. PubMed ID: 28829877
    [Abstract] [Full Text] [Related]

  • 20. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan 22; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.